Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Down 44.8% in December

Repare Therapeutics Inc. (NASDAQ:RPTX) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 194,336 shares, a decrease of 44.8% from the December 15th total of 352,361 shares. Based on an average trading volume of 1,759,426 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the shares of the stock are short sold. Currently, 0.5% of the shares of the stock are short sold. Based on an average trading volume of 1,759,426 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Several research firms recently commented on RPTX. TD Cowen downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. Cowen cut shares of Repare Therapeutics to a “hold” rating in a research report on Monday, November 17th. HC Wainwright reduced their price target on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, October 27th. Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.00.

Repare Therapeutics Price Performance

Shares of RPTX opened at $2.60 on Thursday. The stock has a market cap of $111.95 million, a PE ratio of -1.54 and a beta of 0.97. The firm has a 50-day simple moving average of $2.23 and a two-hundred day simple moving average of $1.86. Repare Therapeutics has a 1-year low of $0.89 and a 1-year high of $2.66.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.43. The company had revenue of $11.62 million for the quarter, compared to analysts’ expectations of $7.50 million. As a group, sell-side analysts expect that Repare Therapeutics will post -2.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repare Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lantern Wealth Advisors LLC purchased a new stake in Repare Therapeutics in the third quarter valued at approximately $35,000. Quinn Opportunity Partners LLC purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $56,000. XTX Topco Ltd bought a new position in shares of Repare Therapeutics during the second quarter worth about $60,000. Squarepoint Ops LLC bought a new stake in Repare Therapeutics during the third quarter valued at $115,000. Finally, Militia Capital Partners LP bought a new stake in Repare Therapeutics in the second quarter valued at $166,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.